Valuation: Black Diamond Therapeutics, Inc.

Market Cap 10Cr 8.78Cr 8.11Cr 7.57Cr 14Cr 948.07Cr 15Cr 98Cr 38Cr 467.72Cr 38Cr 37Cr 1.62TCr P/E 2026 *
-2.7x
P/E 2027 * -1.74x
Enterprise Value 10Cr 8.78Cr 8.11Cr 7.57Cr 14Cr 948.07Cr 15Cr 98Cr 38Cr 467.72Cr 38Cr 37Cr 1.62TCr EV / Sales 2026 *
18.1x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+2.00%
1 week+10.31%
Current month-20.00%
1 month-21.42%
3 months-12.51%
6 months-28.67%
Current year-26.91%
1 week 1.61
Extreme 1.61
1.92
1 month 1.6
Extreme 1.6
2.31
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
12.48
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 50 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
19/06
NEA Management Co. LLC
OtherCompany 0 0%
19/06Free

Director

8,961 0.0156%
19/06Free

Director

7,907 0.0138%
Change 5-day change 1-year change 3-year change Capi.($)
+2.00%+10.31%-28.39%-64.83% 10Cr
+2.01%-1.50%+70.46%+125.32% 5.58TCr
+6.76%+18.10%+91.66%+104.09% 5.57TCr
-0.47%+3.35%-12.03%-13.22% 2.38TCr
+1.24%+4.01%+5.57%+403.55% 2.27TCr
+5.43%+6.26%+38.06%-29.63% 1.61TCr
+0.02%+5.88%+23.34%+184.46% 1.36TCr
+9.96%+15.98%+157.65%+310.89% 1.48TCr
+0.85%+3.53%+75.64%+130.11% 1.22TCr
-0.25%+8.66%+163.14%+166.52% 1.18TCr
Average +2.69%+7.53%+58.51%+131.73% 2.27TCr
Weighted average by Cap. +3.24%+7.70%+66.12%+140.39%

Financials

2026 *2027 *
Net sales 55.56L 48.64L 44.91L 41.94L 78.94L 53Cr 80.74L 5.4Cr 2.09Cr 26Cr 2.09Cr 2.04Cr 90Cr -
Net income -4.05Cr -3.54Cr -3.27Cr -3.06Cr -5.75Cr -382.65Cr -5.88Cr -39Cr -15Cr -188.77Cr -15Cr -15Cr -655.41Cr -7Cr -6.13Cr -5.66Cr -5.29Cr -9.95Cr -662.23Cr -10Cr -68Cr -26Cr -326.7Cr -26Cr -26Cr -1.13TCr
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
30/26/30 $1.770 +1.14% 1,04,666
29/26/29 $1.750 +2.34% 11,54,453
26/26/26 $1.710 +0.59% 85,78,830
25/26/25 $1.700 -8.60% 19,32,360
24/26/24 $1.860 +15.53% 28,71,541
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.750USD
Average target price
9.857USD
Spread / Average Target
+463.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock